Dennies Varughese, Pharm.D., a director in Sterne Kessler’s Trial & Appellate Practice Group, is a trial attorney and globally recognized strategic advisor for pharmaceutical clients. Dennies specializes in the full range of intellectual property disputes, having handled numerous high-stakes patent and trademark litigation in district courts, as well as many contested proceedings before the U.S. Patent Trial and Appeal Board (“PTAB”) at the Patent Office.

Ranked as a leading life sciences litigator by various national accrediting agencies, Dennies has been lead trial counsel on dozens of high-stakes district court cases and PTAB matters involving blockbuster pharmaceuticals, on both the brand and generic side, including: Abilify® (aripiprazole), Zytiga® (abiraterone), Dymista® (azelastine/fluticasone), Cialis® (tadalafil), Gilenya® (fingolimod), Nexium 24® (esomeprazole OTC), Revlimid® (lenalidomide), and many others. Notably, he successfully defeated injunction motions clearing the way for first-wave generics into the lucrative market for Abilify®, at that time the largest pharmaceutical litigation ever. Dennies has also handled many cases for market leaders in other industries, including biopharmaceuticals, chemicals, medical devices, diagnostics, telecommunications, and electronics.

In addition to patent disputes, Dennies has extensive experience in anti-counterfeiting and trademark enforcement. He served as lead counsel for Juul Labs, Inc. in various trademark and trade dress disputes against unauthorized copyists of Juul’s highly successful Electronic Nicotine Delivery Systems.

Dennies also has an active practice before the PTAB involving inter partes review (“IPR”) and post-grant review (“PGR”) proceedings. He was involved in the first ever IPR filed in an ANDA case (Vigamox®) in 2012, and served as lead counsel in the only to-date CBM in a pharmaceutical case (Xyrem®). A full listing of Dennies’ representative matters before the PTAB can be found below. Dennies is a contributing author of Patent Office Litigation, a comprehensive treatise exploring all aspects of contested proceedings before the Patent Office.

Dennies, a frequent lecturer and author, is often quoted in legal publications and is a thought leader on Paragraph IV disputes. He is sought after by generic and brand companies alike for strategic advice on FDA regulatory and early commercialization strategies, product targeting, 505(b)(2) product design, at-risk launch, 180-Day marketing exclusivity and forfeiture, labeling carve-outs, patent settlement and licensing, supply and distribution agreements, drug products liability, and antitrust issues bearing on patent settlements.

Prior to his legal career, Dennies completed a post-doctoral fellowship at Bristol-Myers Squibb Co., worked within GlaxoSmithKline’s Medical Affairs division, and served as an adjunct professor of pharmacy at Rutgers University. He was also a licensed pharmacist in Pennsylvania.

Dennies received his J.D. from Temple University Beasley School of Law. In law school, he was a member of the Temple Law Review, was awarded the Barrister Award for excellence in trial advocacy, the Podwil Memorial Prize for excellence in intellectual property, and the Matkoff Scholarship award. He graduated with honors, cum laude. He earned his Pharm.D. from the University of the Sciences, Philadelphia.

Dennies grew up in Philadelphia and he loves the Philadelphia Eagles.

Hatch-Waxman Litigation Engagements

  • AstraZeneca Pharmaceuticals LP v. Intas Pharmaceutical Ltd. (currently representing Intas in Hatch Waxman litigation over SEROQUEL® XR) (D.N.J.) (08-cv-04804)
  • AstraZeneca Pharmaceuticals LP v. Glenmark Generics, Inc. (currently representing Glenmark in multiple Hatch Waxman patent litigations over CRESTOR®) (D. Del.) (10-cv-00341; 10-cv-00543
  • Takeda Pharmaceuticals Co. v. Torrent Pharmaceuticals Ltd. (represented Torrent in Hatch Waxman patent litigation over ACTOS®) (S.D.N.Y.) (09-cv-6051)
  • GlaxoSmithKline v. Glenmark Generics, Inc. (represented Glenmark in Hatch Waxman patent litigation over MALARONE®) (D. Del) (09-cv-00608)

Patent Litigation Engagements

  • Teva v. Glenmark Pharmaceuticals, Inc. (represented Glenmark in patent litigation over carvedilol) (D.N.J.) (08-cv-4355)
  • Typhoon Touch Technologies v. Motion Computing et al.(represented Typhoon Touch in patent litigation over portable touch screen computers) (E.D. Tex) (07-cv-00546)
  • Nexans, Inc. v. General Cable Corporation (represented General Cable in patent litigation over high-speed data communication cables) (E.D. Pa.) (07-cv-02296)
  • Nutrition 21, Inc. v. General Nutrition Company (assisted in representation of Nutrition 21 in patent litigation over chromium picolinate) (E.D. Tex) (05-cv-00291)

PTAB Engagements

  • Amneal Pharmaceuticals LLC et al. v. Allergan, Inc. et al. (representing Amneal in IPR proceedings concerning an acne drug) (IPR2018-00608, IPR2019-00207)
  • Argentum Pharmaceuticals LLC et al. v. Cipla Limited et al. (represented Cipla in an IPR of a patent covering DYMISTA®) (IPR2017-00807)
  • Wockhardt Bio AG et al. v. Janssen Oncology, Inc. et al. (represented Wockhardt in an IPR of a patent covering ZYTIGA®) (IPR2016-01582)
  • Wockhardt Bio AG v. Jazz Pharmaceuticals, Inc. (represented Wockhardt in an IPR of a patent claiming microbe-resistant formulations) (IPR2016-00370)
  • Amneal Pharmaceuticals LLC v. Jazz Pharmaceuticals, Inc. (IPR2015-00547, -00546, -00545) (CMB2014-00150, -00149)
  • Amneal Pharmaceuticals LLC v. Endo Pharmaceuticals, Inc. (IPR2014-01365, -00361, -00360, 00160)
  • Ricoh Americas Corporation v. MPHJ Technology Investments, Inc. (IPR 2013-00302)

  • IAM Patent 1000, “Washington, D.C.: Patent Litigation (Bronze Band)” (2023 – 2018)
  • LMG Life Sciences, “Life Sciences Star” (2023 – 2018)
  • Super Lawyers, “Super Lawyer – Washington D.C.” (2023 – 2018)
  • Super Lawyers, “Rising Star – Washington D.C.” (2017 – 2014)

  • J.D., Temple University Beasley School of Law, cum laude
  • Pharm.D., University of the Sciences

  • District of Columbia
  • New Jersey
  • Pennsylvania
  • United States Patent & Trademark Office

  • American Inns of Court
  • American Society of Health-System Pharmacists
  • Philadephia Bar Association

Speaking Engagement

2023 Focus on Pharma

Washington, DC, April 14, 2023 8:30 AM - 6:00 PM PST

Speaking Engagement

International IP Skills Summit (IIPSS)

Hyderabad, India, Hyatt Place Hyderabad, February 26, 2020 12:00 AM - 11:59 PM PST

Speaking Engagement

13th Annual Paragraph IV Disputes

New York, NY, Conrad New York, April 29, 2019

4th Annual Pharma IPR India

February 11, 2015

Related Resources

From Dennies Varughese, Pharm.D.

In the News

January 4, 2024

Victory in the courtroom: Sweegen's Victory Redefines Stevia Sweetener

Korea IT Times

Firm Announcements

January 3, 2024

Federal Circuit Affirms Sweet Win for SweeGen in Patent Invalidity Battle

Sterne, Kessler, Goldstein & Fox

In the News

January 2, 2024

Fed. Circ. Backs Calif. Decision Invalidating Sweetener IP

Law360

In the News

November 7, 2023

Fed. Circ. Judge Casts Doubt On Sweetener Enzyme Patents

Law360

Press Release

September 21, 2023

LMG Life Sciences Ranks Sterne Kessler and Seven Directors for Patent Litigation and Prosecution

Sterne, Kessler, Goldstein & Fox

Firm Announcements

August 29, 2023

U.S. District Court Affirms Immigrant Children’s Constitutional Rights

Sterne, Kessler, Goldstein & Fox

Press Release

April 24, 2023

Super Lawyers Recognizes 14 Sterne Kessler Attorneys as 2023 “Super Lawyers” and “Rising Stars”

Sterne, Kessler, Goldstein & Fox

Press Release

September 22, 2022

Sterne Kessler and Seven Directors Recognized in LMG Life Sciences Rankings for the 10th Consecutive Year

Sterne, Kessler, Goldstein & Fox

In the News

September 15, 2022

Novartis Tells FDA Skinny Labels Won't Work With $3.5B Drug

Law360

In the News

September 12, 2022

Gilead Settles Patent Fight With Generic Drugmakers Over HIV Drugs

Reuters

In the News

September 12, 2022

Gilead Settles HIV Drugs Patent Suit on Eve of Bench Trial

Law360

Firm Announcements

July 14, 2022

Sterne Kessler Client Catalyst Pharmaceuticals, Inc. Reaches Patent Litigation Settlement

Sterne, Kessler, Goldstein & Fox

Firm Announcements

May 25, 2022

Sterne Kessler Team Secures Summary Judgment of Patent Invalidity on Behalf of Sweegen, Inc. in District Court

Sterne, Kessler, Goldstein & Fox

In the News

May 24, 2022

Stevia Patent Claims Fall After SweeGen Challenge

Law360

In the News

May 24, 2022

Sweegen Wins Challenges to Rival’s Artificial Sweetener Patents

Bloomberg Law

Press Release

May 1, 2022

Super Lawyers Recognizes 14 Attorneys as 2022 “Super Lawyers” and “Rising Stars”

Sterne, Kessler, Goldstein & Fox

In the News

March 31, 2022

EU Unified Patent Court Spurs Delight and Fear for Experts

Law360

In the News

March 14, 2022

Almirall Loses Appeal on Acne Treatment Patent at Fed. Cir.

Bloomberg Law

In the News

March 14, 2022

Fed. Circ. Affirms PTAB's Ax of Acne Drug Patent

Law360

In the News

January 12, 2022

Fed. Circ. Doubts PTAB Erred in Axing Almirall Acne Drug IP

Law360

Press Release

September 29, 2021

Sterne Kessler and Seven Directors Earn Top-Tier Designations in 2021 LMG Life Sciences Rankings

Sterne, Kessler, Goldstein & Fox

In the News

March 25, 2021

How 2020 ANDA Litigation Played Out – And What to Expect for 2021

Managing IP

In the News

March 4, 2021

How Counsel Balance USPTO and Court Edicts on Section 101

Managing IP

Press Release

October 6, 2020

Firm and Seven Directors Recognized in 2020 LMG Life Sciences Rankings

Sterne, Kessler, Goldstein & Fox P.L.L.C.

Press Release

September 24, 2020

Sterne, Kessler, Goldstein & Fox Wins Two 2020 LMG Life Sciences Americas Awards

Sterne, Kessler, Goldstein & Fox P.L.L.C.

Press Release

June 16, 2020

Sterne, Kessler, Goldstein & Fox and 15 Directors Earn Top Rankings in IAM Patent 1000

Sterne, Kessler, Goldstein & Fox P.L.L.C.

In the News

June 4, 2020

Fed. Circ. Says It Can't Award Atty Fees Tied To PTAB Cases

Law360

In the News

June 1, 2020

Generics' 2nd Challenge To Acne Drug IP Succeeds At PTAB

Law360

Press Release

April 30, 2020

Sterne, Kessler, Goldstein & Fox Attorneys Named 2020 Super Lawyers and Rising Stars

Sterne, Kessler, Goldstein & Fox P.L.L.C.

In the News

April 1, 2020

PTAB Upholds 3 Teva Migraine Patents Challenged By Eli Lilly

Law360

In the News

November 13, 2019

Drug Cos. May Rethink Patent Strategy After Fed. Circ. Ruling

Law360

Press Release

June 12, 2019

Sterne Kessler Prominent Again in Intellectual Asset Management Magazine’s "IAM Patent 1000"

Sterne, Kessler, Goldstein & Fox P.L.L.C

In the News

May 14, 2019

Fed. Circ. Backs PTAB Ax Of J&J Prostate Cancer Drug Patent

Law360

In the News

May 14, 2019

Johnson & Johnson loses appeal to revive Zytiga patent

Reuters

In the News

May 14, 2019

Challenges To Different Patents Not Serial, PTAB Says

Law360

In the News

March 14, 2019

Fed. Circ. Wary Of Ruling On AIA Patent Challenge Meaning

Law360

In the News

December 4, 2018

J&J Tells Fed. Circ. Judge Was Wrong To Nix Zytiga Patent

Law360

In the News

October 29, 2018

NJ Judge Invalidates Patent For Janssen Cancer Drug Zytiga

Law360

Press Release

September 25, 2018

Sterne Kessler Recognized By LMG Life Sciences Among The Top IP Firms and Attorneys

Sterne, Kessler, Goldstein & Fox

Firm Announcements

July 26, 2018

Sterne Kessler Prevails in the Release of Child from a Juvenile Detention Center

Sterne, Kessler, Goldstein & Fox

In the News

June 20, 2018

PTAB's Doors Would Be Closed To Generics Under Hatch Bill

Law360

Bylined Articles

March 16, 2018

The 505(b)(2) Drug Approval Pathway: A Potential Solution for the Distressed Generic Pharma Industry in an Increasingly Diluted ANDA Marketplace?

Bloomberg BNA Dennies Varughese, Pharm.D., Gaby L. Longsworth, Ph.D.

Press Release

April 11, 2017

Sterne, Kessler, Goldstein & Fox Attorneys Named 2017 Super Lawyers

Dennies Varughese, Pharm.D., Gaby L. Longsworth, Ph.D.

Books and Chapters

February 17, 2017

Patent Office Litigation - Second Edition 2017

Thomson Reuters Westlaw Multiple Authors

Bylined Articles

May 6, 2016

The DAIMLER Series: Lessons In Personal Jurisdiction for Biologic and Biosimilar Litigants

Bloomberg BNA: Pharmaceutical Law & Industry Report Dennies Varughese, Pharm.D.

Bylined Articles

September 11, 2015

The DAIMLER Series: Five Personal, Specific Lessons Learned for Hatch-Waxman ANDA Litigants

Bloomberg BNA Pharmaceutical Law & Industry Report Dennies Varughese, Pharm.D.

Bylined Articles

July 3, 2015

The DAIMLER Series: District Courts Analyze Personal Jurisdiction in ANDA Cases

Bloomberg BNA: Pharmaceutical Law & Industry Report Dennies Varughese, Pharm.D.

Firm Announcements

April 16, 2015

Sterne Kessler Successfully Represents Alembic Pharmaceuticals Limited in Launching Generic Drug

Chandrika Vira, Dennies Varughese, Pharm.D.

Bylined Articles

April 9, 2015

Some Declaratory Judgment Guidance for ANDA Litigants

Law360 Dennies Varughese, Pharm.D.

Press Release

January 8, 2015

Sterne Kessler Announces Election of Largest Director Class in Firm History

Dennies Varughese, Pharm.D.

In the News

April 16, 2014

Glenmark Sues Sanofi to Clear Way for Antidiuretic

Law360 Dennies Varughese, Pharm.D.

Bylined Articles

March 11, 2014

IPR: A 2nd Bite At The Apple For Hatch-Waxman Litigants

Law360 Dennies Varughese, Pharm.D.